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Abstract 
Background: Hypersensitivity reaction to certain allergens plays a role in the pathogenesis of inflammatory bowel 
disease (IBD). This study aims to observe the effect of specific immunotherapy in a group of IBD patients.
Methods: Patients with both ulcerative colitis (UC) and food allergy were recruited into this study. Food allergy was 
diagnosed by skin prick test and serum specific IgE. The patients were treated with specific immunotherapy (SIT) and 
Clostridium butyricum (CB) capsules.
Results: After treating with SIT and CB, the clinical symptoms of UC were markedly suppressed as shown by reduced 
truncated Mayo scores and medication scores. The serum levels of specific IgE, interleukin (IL)‑4 and tumor necrosis 
factor (TNF)‑α were also suppressed. Treating with SIT alone or CB alone did not show appreciable improvement of 
the clinical symptoms of UC.
Conclusions: UC with food allergy can be ameliorated by administration with SIT and butyrate‑production 
probiotics.
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Background
Inflammatory bowel disease (IBD) is a kind of chronic 
inflammatory bowel disease, including Crohn’s dis-
ease (CD) and chronic nonspecific ulcerative colitis 
(UC). The pathogenesis of IBD is unknown. Numerous 
reports implicate that immune abnormalities, infection 
or genetic factors contribute to IBD [1]. The colon is the 
most common location of IBD. Because of the high den-
sity of microbes in the colon and the hyper-reactivity of 
the immune system in IBD patients, it is assumed that 
over-reaction to microbes or their products is a major 
causative factor of IBD. However, so far we do not have 
satisfactory therapies for IBD.
It has been noted that food allergy is associated with 
the pathogenesis of IBD [2, 3]. Food allergy is an adverse 
reaction of the immune system to innocent nutritional 
elements, such as eggs, fish, cow milk, etc. The pathologic 
feature of food allergy is that antigen-specific IgE forms 
a complex with the high affinity receptor of IgE on the 
surface of mast cells, which makes mast cells sensitized. 
Upon re-exposure to the specific antigen, the sensitized 
mast cells can be activated and release a series of chemi-
cal mediators, such as histamine, leukotrienes, tryptase, 
tumor necrosis factor (TNF)-α, etc. These chemical 
mediators are capable of inducing inflammation in the 
local tissue.
The current therapeutic remedies of IBD include drug 
treatment (such as immunomodulators and biologic 
therapies); the formation of intestinal stenosis needs 
surgical treatment. Probiotic treatment is also a thera-
peutic option [4]. In fact, the current therapies for IBD 
have important limitations currently. Aminosalicylates 
2–4 are commonly used for UC, but the efficacy is mod-
est. Steroids are effective, but cause severe complications. 
Anti-tumor necrosis factor (TNF)-α antibody is effective 
in some IBD patients [5], but may cause serious infection 
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in some predispose patients [6]. Therefore, new treat-
ment remedies are needed. The therapies for food allergy 
are also limited. Avoidance of the offending foods is the 
major method. Another remedy for food allergy treat-
ment is the allergen specific immunotherapy (SIT), which 
is recommended to be a specific remedy for food allergy 
by the World Health Organization [7].
Published data indicate that probiotics have therapeu-
tic effects on immune disorders [8]. Probiotics are bacte-
ria that can provide healthy benefit when consumed. The 
benefits of probiotics include the decrease of pathogenic 
microorganisms in the intestine, regulation of gastroin-
testinal function, to strengthen the function of immune 
system, to improve the skin’s function, etc. [9]. Adminis-
tration of probiotics has got promising therapeutic effects 
[10]. Probiotics also show benefit in the improvement of 
IBD symptoms while the methodology in their adminis-
tration needs to be further investigated [4].
Based on the information above, we hypothesize that 
SIT can be a specific remedy for IBD with food allergy. In 
this study, we treated a group of UC/food allergy patients 
with SIT and Clostridium butyricum (CB). The results 
showed a satisfactory alleviation on IBD symptoms.
Methods
Ethics approval and consent to participate
This study was approved by the Human Research Ethic 
Committee at Tongji University and Zhengzhou Univer-
sity. The experiments were performed in accordance with 
the approved guidelines. An informed, written consent was 
obtained from each patient. The project was registered as a 
clinical study at the Clinical Practice Registration Bureau of 
Shanghai, China (CPRB#2013086; March 21, 2013).
UC patients with food allergy
Patients with both UC and food allergy were diagnosed 
by physicians at our clinic following the published proce-
dures [11, 12]. The UC-related information is presented 
in Table 1. The diagnosis of food allergy was based on the 
disease history, skin prick test (SPT) (Table 2) with food 
antigen extracts and serum specific IgE (>0.35 IU/ml).
Selection of non‑IBD patients
To compare the incidence of food allergy between IBD 
patients and non-IBD patients, non-IBD subjects were 
also recruited with the criteria: no IBD disease history; 
no other organ diseases; no autoimmune diseases; no 
cancer. The diagnosis of food allergy in non-IBD subjects 
was in the same procedures as of IBD group.
Table 1 Demographic data
WBC white blood cell count, Before before treatment, After after treatment
* p < 0.01, compared with the results before treatment in the same group
Character‑
istic
Placebo SIT CB SIT/CB
(N = 22) (N = 23) (N = 25) (N = 26)
Age (years) 43.5 ± 11.2 41.8 ± 12.5 42.2 ± 8.6 43.3 ± 10.7
Male‑no. (%) 12 (54.5) 11 (47.8) 14 (56) 14 (53.8)
Body weight 
(kg)








6.2 ± 5.2 5.8 ± 6.1 6.3 ± 4.9 6.3 ± 5.4
Mayo clinic 
score (MCS)
8.5 ± 1.2 8.6 ± 1.8 8.6 ± 1.1 8.6 ± 1.6
Partial MCS 6.1 ± 1.1 6.0 ± 1.4 6.1 ± 1.4 6.0 ± 1.5




1.2 ± 1.1 1.1 ± 0.9 1.2 ± 0.8 1.1 ± 0.8
Site of disease‑no. (%)
 Rectum and 
sigmoid 
colon
4 (18.2) 6 (27.3) 5 (20) 6 (23.1)
 Left side of 
colon
6 (27.3) 6 (27.3) 8 (32) 6 (23.1)
 Proximal 
colon
7 (31.8) 5 (21.7) 3 (8) 5 (19.2)
 All of the 
colon
5 (22.7) 6 (27.3) 9 (36) 9 (34.6)
Medication‑no. (%)









6 (27.3) 5 (21.7) 7 (28) 7 (26.9)
 No medica‑
tion
6 (27.3) 9 (39.1) 6 (24) 6 (23.1)
Fecal calprotectin
 Before 255.6 (38.6) 266.8 (42.5) 249.5 (41.3) 253.8 (39.5)
 After 244.8 (36.8) 258.3 (41.7) 241.5 (39.5) 68.3 (8.5)*
Hemoglobin (g/l)
 Before 122.5 ± 15.8 123.8 ± 17.6 125.6 ± 15.2 122.8 ± 14.5
 After 124.3 ± 14.2 123.1 ± 13.6 125.2 ± 11.5 144.6 ± 11.1*
WBC (×10−9/l)
 Before 8.6 ± 3.2 8.6 ± 3.5 8.6 ± 3.2 8.5 ± 3.6
 After 8.3 ± 2.5 8.2 ± 4.1 8.2 ± 2.4 6.1 ± 1.4*
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SPT
SPT was carried out in our clinic using commercial food 
extract reagents (Greer Company; Taibei, China). Food 
extracts included shrimp, eggs, walnuts, hazelnuts, soy, 
peanuts, fish and cow’s milk. Saline was used as a nega-
tive control. Histamine (1 mg/ml) was used as a positive 
control. SPT was defined as positive when the diameter 
of the wheal was 3 mm larger than a negative control at 
15 min. The SPT results are presented in Table 2.
UC clinical symptom assessment
The truncated Mayo score system (Table 3) was employed 
to assess the clinical UC symptoms (mainly including 
rectal bleeding and stool frequency), which were evalu-
ated before and after the treatment.
Medication score assessment
If necessary, the patients were allowed to be treated with 
prednisone based on previous reports [13]. The medi-
cation scores (Table  4) were recorded for each patient 
1  month before the therapy and the last month during 
the observation period.
Therapies
Patients were randomized to one of four groups: (1) SIT 
only (2) CB only, or (3) Combination SIT + CB, (4) Pla-
cebo. A 6-month SIT was carried out for each patient in 
SIT only group and the combination SIT  +  CB group. 
Briefly, UC patients were treated with the sensitized 
foods once a week for 10  weeks. The weekly increment 
dosage is presented in Table  5. From the 11th  week to 
the end of the 6th month, the patients took the sensitized 
foods at tenfolds of the basic dose every 2 weeks. In the 
CB group, patients were prescribed with CB capsules 
(420  mg, two times a day) throughout the entire obser-
vation period. In the placebo group, patients were given 
saline instead of allergen vaccine, and the capsules con-
tained vehicle instead of CB.
Collection of peripheral blood samples
Peripheral blood samples (20  ml per patient) were col-
lected from each patient before and after the therapy. 
The sera were isolated by centrifugation (3000  rpm) for 
10 min at 4 °C, and stored at −80 °C until use.
Determination of serum Ig and cytokines
The serum levels of specific IgE and IgG4 levels were 
determined by the ImmunoCAP 250 system (Phadia, 
Uppsala, Sweden). The serum levels of IL-4, IL-17, IFN-γ 
and TNF-α were determined by enzyme-linked immuno-
assay (ELISA) with commercial reagent kits (R&D Sys-
tems, Minneapolis, MN) following the manufacturer’s 
instructions.
Measurement of fecal calprotectin
Patients provided a stool sample for the measurement 
of calprotectin at the clinic visits. Fecal calprotectin 
was measured by ELISA with a reagent kit following the 
manufacturer’s instructions (Enke Biotech, Shenzhen, 
China). Laboratory personnel were blinded to the clini-
cal data.
Statistics
Data are presented as mean ± SD, or percentage. Dif-
ference between groups was determined by Student 
t test, or χ2 test. The significant criterion was set as 
p < 0.05.
Table 2 Results of skin prick test
Some patients were sensitized to more than one antigen. These are the most common food allergens in China. The number “96” is total IBD patients with food allergy
Fish Egg Soy Hazelnut Shrimp Walnut Milk Peanut
Patients 15/96 28/96 28/96 16/96 29/96 16/96 35/96 21/96
Percentage (15.6) (29.2) (29.2) (16.7) (30.2) (16.7) (36.5) (21.9)
Table 3 Truncated Mayo scores
Rectal bleeding scale
 0. No blood seen
 1. Streaks of blood with stool less than half of the time
 2. Obvious blood with stool most of the time
 3. Blood alone passed
Stool frequency scale
 0. Normal stool frequency per day
 1. 1–2 stools greater than normal per day
 2. 3–4 stools greater than normal per day
 3. ≥5 stools greater than normal per day
Table 4 Medication scores
The dosage indicates daily dose
Mesalamine (g) Scores Prednisone (mg) Scores
1 1 10 1
2 2 20 2
3 3 30 3
4 4 40 4
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Results
Patients
Patient information is presented in Fig. 1. From 338 UC 
patients, 102 (30.17 %) UC patients were diagnosed food 
allergy and were recruited into this study. Among the 
patients, six withdrew from the study; thus, 96 patients 
completed the 6-month study. No patients were treated 
with SIT or CB or anti-TNF-α antibody previously. As 
shown by Table 1, no important difference in the demo-
graphic data between groups. On the other hand, we 
compared the incidence of food allergy between IBD 
patients and those without IBD. In total 342 non-IBD 
subjects (male: 170; female: 172; age: 42.6  ±  11.8  years 
old) were recruited, in which 8 (2.34 %) subjects had food 
allergy. The incidence of food allergy in non-IBD subjects 
was significantly less (p < 0.01) than IBD patients.
Clinical outcomes of the therapy
As shown by Fig. 2a, the truncated Mayo scores reduced 
significantly in the SIT/CB group. In the patients treated 
with SIT alone or CB alone, the truncated Mayo scores 
were also reduced, but did not reach the significant 
criterion.
The medication scores were also significantly reduced 
in the patients treated with SIT/CB. Like the truncated 
Mayo scores, patients treated with SIT alone or CB alone 
did not show significant improvement of the medication 
scores (Fig. 2b).
We also assessed the changes of fecal calprotectin levels 
in the patients before and after the therapy. The results 
showed that the levels of fecal calprotectin were signifi-
cantly reduced in patients treated with both SIT and CB, 
while those treated with either placebo, or SIT alone, or 
CB alone did not show significant changes of the fecal 
calprotectin (Fig. 2c).
Effect of the therapy on serum IgE, IgG4 and CD4+ T cell 
cytokines
The blood samples were collected from each patient 
before and after the therapy, and analyzed by ELISA. 
The results showed that the antigen-specific IgE, but not 
IgG4, IL-4, IFN-γ, IL-17 and TNF-α were detected in 
all the IBD patients with food allergy. After the therapy, 
patients treated with SIT/CB showed significantly lower 
levels of antigen-specific IgE, higher levels of antigen-
specific IgG4, lower levels of IL-4 and TNF-α; the lev-
els of IFN-γ and IL-17 were not changed significantly. 
In those patients treated with placebo, SIT alone or CB 
alone, all the six parameters remained the same as before 
the therapy (Fig. 3).
Table 5 Food antigen dosage
Fish Egg Soy Hazelnut Shrimp Walnut Milk Peanut
3 g 1/10 egg 3 g 3 g 3 g 3 g 10 ml 3 g
Fig. 1 Patients completed the 6 month therapy. In total 102 UC patients were recruited into this study. The patients were randomly divided into 
four groups. Among them, two patients withdrew for SIT adverse reaction; one withdrew for IBD symptom exaggerated; three withdrew for per‑
sonal reasons. Thus, 96 patients completed the 6 month therapy
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Discussion
IBD has had a tremendous negative impact on human 
health and social economy. The current therapies for IBD 
are not satisfactory. Thus, to develop novel therapeutic 
strategies is of significance. To this end, we developed 
a novel treating strategy for a fraction of IBD patients. 
We treated IBD patients with food allergy with SIT and 
CB. The results showed profound improvement of IBD 
clinical symptoms, including reducing the truncated 
Mayo scores and medication scores, as well as reduced 
the serum levels of antigen-specific IgE, IL-4, IL-17, 
TNF-α, and fecal calprotectin while those treated with 
either SIT alone or CB alone did not induce appreciable 
improvement.
The association between food allergy and the patho-
genesis of IBD has been noted for a long time. Levo et al. 
[14] in 1980s observed high levels of specific IgE in IBD 
patients and suggested an association between food 
allergy and IBD. Joachime [15] noted that people with 
IBD reported that some foods made them feel better and 
some foods made them feel worse. Cashman [16] in a 
review paper proposed that nutrition was an important 
etiological factor for IBD. Our data are in line with these 
reports by showing high levels of specific IgE in a group 
of IBD patients with food allergy. The clinical data have 
been supported by data from animal model study [3].
It is proposed that multiple factors contribute to the 
pathogenesis of IBD. Food allergy is one of the major fac-
tors in the etiology of IBD [17]. The present data showed 
that the high levels of specific IgE, IL-4 and TNF-α 
in the IBD patients with food allergy were down regu-
lated after the therapy of SIT and CB, while the levels 
Fig. 2 Clinical outcomes of the therapy. The bars indicate the outcomes of the therapy, including truncated Mayo scores (a), medication scores 
(b) and the levels of fecal calprotectin (c), which were recorded before and after completion of the therapy. *p < 0.01, compared with the placebo 
group. The patient numbers are the same as Fig. 1
Fig. 3 Effect of the therapy on serum IgE, IgG4 and CD4+ T cell cytokines. Peripheral blood samples were collected from each patient before and 
after the therapy. The sera were analyzed by ELISA. The bars indicate the serum levels of SIgE (a), SIgG4 (b), IL‑4 (c), IFN‑g (d), IL‑17 (e) and TNF‑alpha 
(f). The data are presented as mean ± SD. *p < 0.01, compared to the “before” values
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of antigen-specific IgG4 were up regulated. The data 
implicate that besides food allergy, other unknown fac-
tors may also exist in these patients to contribute to the 
pathogenesis of IBD. To up regulate the levels of antigen-
specific IgG4 was observed in SIT in previous reports 
[18]. IgG4 may neutralize IgE [19, 20] and block mast 
cell activation [21]. Our data show that the serum levels 
of IgE and TNF-α were suppressed in the patients with 
IBD and food allergy after the treatment with SIT and 
CB, indicating that the therapy also blocked mast cell 
activation since mast cells are one of the major sources 
of TNF-α in the body [22].
Since patients are being treated for food allergy, the 
results maybe confounded if improvement was due to 
food allergy rather than treatment of inflammation in 
patients with both. In other words, the data show that 
treating with only SIT did not improve outcome in these 
patients, how to explain the combination of CB with 
SIT was truly treating IBD or if it was having a greater 
impact in food allergy related diarrhea. The data suggest 
that SIT and CB act synergistically in the generation of 
the therapeutic effect. Our another study showed that in 
a food allergy animal model study, the histone deacety-
lase (HDAC)1 levels in B cells were up regulated. HDAC1 
suppressed the expression of IL-10 and facilitated the 
expression of IgE. Employing the HDAC inhibitor fea-
ture, CB facilitated SIT to generate regulatory B cells via 
releasing butyrate, which is an inhibitor of HDAC1. The 
induced regulatory B cells fulfilled the immune suppres-
sor function in the inhibition of the allergic inflammation 
[23]. Others also reported that administration of SIT and 
CB inhibited asthma clinical symptoms [24].
In summary, combination of SIT and CB efficiently 
inhibited the clinical symptoms of IBD patients with food 
allergy.
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